



National Coverage Determinations & Indiana Medicare Part B LCD's
Clinical Diagnostic Laboratory Services
Effective: January 2025 (Updated June 20, 2025)

Estimated Patient Cost

TEST DESCRIPTION	INCLUDES TESTS	Est. cost	Reason
NATIONAL COVERAGE DETERMINATIONS (NCD'S)			
Alpha Fetoprotein (190.25)	82105 — Alpha-fetoprotein, serum	\$36.00	C
Blood Counts (CBC) (190.15)	85004 - Blood count; automated differential white blood cell (WBC) count 85007 – Blood smear, microscopic examination with manual differential WBC count 85008 – Blood smear, microscopic examination without manual differential WBC count 85013 – Blood counts, spun microhematocrit 85014 – Blood counts, hematocrit (Hct) 85018 – Blood counts, hemoglobin 85025 – blood counts, complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count. 85027 – Blood counts, complete (CBC), automated (Hcb, Hct, RBC, WBC and platelet count) 85032 – Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each 85048 – Blood counts, leukocyte (WBC) automated. 85049 – Blood count; platelet, automated	\$30.00 \$24.00 \$30.00 \$30.00 \$38.00 \$12.00 \$30.00 \$30.00	C
Blood Glucose Testing (190.20) (Also see Medicare Preventative Services Quick Reference)	82947 – Glucose; quantitative, blood (except reagent strip) 82948 – Glucose; blood, reagent strip	\$30.00 \$34.00	C, F
Carcinoembryonic Antigen (CEA) (190.26)	82378 – Carcinoembryonic Antigen (CEA)	\$60.00	C
Collagen Crosslinks (190.19)	82523 – Collagen Cross Links, serum 82523 - Collagen Cross Links, 24-hour urine	\$176.00 \$ 60.00	C
Culture-Bacterial (Urine) (190.12)	87086 - Culture, bacterial; quantitative colony count, urine 87088 - Culture, bacterial;with isolation and presumptive identification of isolates, urine	\$50.00 \$28.00	C
Digoxin Therapeutic Drug Assay (190.24)	80162 – Digoxin (therapeutic drug assay)	\$94.00	C
Fecal Occult Blood (190.34) (Frequency guideline exists) (Also see Medicare Preventative Services Quick Reference)	82272 -Blood, occult, by peroxidase activity (eg guaiac), qual. Feces; single spec (dig exam)	\$28.00	C, F
Gamma Glutamyl Transferase (GGT) (190.32)	82977 – Glutamyltransferase, gamma (GGT)	\$30.00	C

Reason for Denial: C = Condition F = Frequency E = Experimental

NCD and LCD with Estimated Patient Cost 1-2025 / Updated 6/20/2025



ALVERNO LABORATORIES

National Coverage Determinations & Indiana Medicare Part B LCD's

Clinical Diagnostic Laboratory Services

Effective: January 2025 (Updated June 20, 2025)

Estimated Patient Cost

Glycated Hemoglobin/Glycated Protein (190.21) Frequency guideline exists (Also see Medicare Preventative Services Quick Reference)	82985 – Glycated protein 83036 – Hemoglobin; glycated (A1C)	\$90.00 \$40.00	C, F
Hepatitis Panel (Acute) (190.33) Screening Frequency guideline exists (Also see Medicare Preventative Services Quick Reference)	80074 - Acute Hepatitis Panel 86704 - Hepatitis B core antibody, Total 86705 - Hepatitis B core antibody IgM 86706 - Hepatitis B surface antibody 86709 – Hepatitis A antibody (HAAb), IgM Antibody 86803 – Hepatitis C antibody	\$130.00 \$50.00 \$118.00 \$46.00 \$124.00 \$50.00	C
HIV Testing (Prognosis including monitoring) (190.13)	87536 – Infectious agent detection by nucleic acid (DNA or RNA); HIV-1 quantification 87539 – Infectious agent detection by nucleic acid (DNA or RNA); HIV-2 quantification	\$614.00	C
HIV Testing (Diagnosis) (190.14) (Also see Medicare Preventative Services Quick Reference)	86689 – Qual. or semi-quant. Immunoassays performed by multiple step methods; HTLV or HIV antibody, confirmatory test (ie, Western Blot) 86701 – Qual. or semi-quant. Immunoassays performed by multiple step methods; HIV-I 86702 - Qual. or semi-quant. Immunoassays performed by multiple step methods; HIV-II 86703 - Qual. or semi-quant. Immunoassays performed by multiple step methods; HIV-I and HIV-II, single assay. 87390 – Infectious agent antigen detection by enzyme immunoassay technique, qual. or semi quant., multiple step, HIV-I. 87391 - Infectious agent antigen detection by enzyme immunoassay technique, qual. or semi quant., multiple step, HIV-II. 87534 – Infectious agent detection by nucleic acid (DNA or RNA); HIV-I, direct probe technique. 87535 - Infectious agent detection by nucleic acid (DNA or RNA); HIV-I, direct probe technique HIV-I, amplified probe technique. 87537 – Infectious agent detection by nucleic acid (DNA or RNA); HIV-II, direct probe technique. 87538 - Infectious agent detection by nucleic acid (DNA or RNA); HIV-II, direct probe technique HIV-I, amplified probe technique.	\$264.00 \$56.00 \$56.00 \$120.00 \$118.00 \$424.00 \$274.00	C
HLA (Histocompatibility Testing) (190.1)	86812 – HLA B-27	\$150.00	C
Human Chorionic Gonadotropin (HCG) (190.27)	84702 – Gonadotropin, chorionic (HCG) quantitative	\$30.00	C

Reason for Denial: C = Condition F = Frequency E = Experimental

NCD and LCD with Estimated Patient Cost 1-2025 / Updated 6/20/2025



ALVERNO LABORATORIES

National Coverage Determinations & Indiana Medicare Part B LCD's

Clinical Diagnostic Laboratory Services

Effective: January 2025 (Updated June 20, 2025)

Estimated Patient Cost

Lipids Testing (190.23) Frequency guideline exists (Also see Medicare Preventative Services Quick Reference)	80061 – Lipid Panel	\$56.00	C, F
	82465 – Cholesterol, serum, total	\$14.00	
	83700 – Lipoprotein, blood; electrophoretic separation and quantitation	\$58.00	
	83701 – Lipoprotein, blood; high resolution fractionation and quantitation of lipoprotein including subclasses when performed.	\$138.00	
	83704 – Lipoprotein, blood; quantitation of lipoprotein particle numbers and lipoprotein particle subclasses	\$88.00	
	83718 – Lipoprotein, direct measurement; high density cholesterol (HDL)	\$24.00	
	83721 – Direct measurement; LDL cholesterol	\$46.00	
	84478 - Triglycerides	\$18.00	
Pap Smear – screening (210.2) Frequency guideline exists (Also see Medicare Preventative Services Quick Reference)	G0145 – Screening Cytopathology, cervical or vaginal	\$76.00	C, F
	P3000 – Screening Papanicolaou smear, cervical or vaginal	\$62.00	
Partial Thromboplastin Time (PTT) (190.16)	85730 – Thromboplastin time, partial (PTT); plasma or whole blood	\$30.00	C
Prostate Specific Antigen (PSA) (190.31) Frequency guideline exists (Also see Medicare Preventative Services Quick Reference)	84153 – Prostate Specific Antigen (PSA); total	\$58.00	C, F
	G0103 – Prostate Cancer Screening; Prostate Specific Antigen Test (PSA)	\$58.00	
Prothrombin Time (PT) (190.17)	85610 – Prothrombin time	\$16.00	C
Serum Iron Studies (190.18)	82728 – Ferritin	\$50.00	C
	83540 – Iron	\$28.00	
	83550 – Iron Binding Capacity	\$28.00	
	84466 - Transferrin	\$110.00	
Thyroid Testing (190.22)	84436 – Thyroxine; total	\$30.00	C
	84439 – Thyroxine; free	\$40.00	
	84443 – Thyroid Stimulating Hormone (TSH)	\$54.00	
	84479 – Thyroid Hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR)	\$30.00	
Tumor Antigen By Immunoassay (CA 15-3/27.29) (190.29)	86300 – Immunoassay for tumor antigen, quantitative; CA 15-3 / 27.29	\$122.00 \$120.00	C
Tumor Antigen By Immunoassay (CA-125) (190.28)	86304 – Immunoassay for tumor antigen, quantitative, CA 125	\$110.00	C
Tumor Antigen By Immunoassay (CA19-9) (190.30)	86301 – Immunoassay for tumor antigen, quantitative; CA 19-9	\$210.00	C

Reason for Denial: C = Condition F = Frequency E = Experimental

NCD and LCD with Estimated Patient Cost 1-2025 / Updated 6/20/2025



ALVERNO LABORATORIES

National Coverage Determinations & Indiana Medicare Part B LCD's

Clinical Diagnostic Laboratory Services

Effective: January 2025 (Updated June 20, 2025)

Estimated Patient Cost

INDIANA PART B LOCAL COVERAGE DETERMINATIONS (LCD'S) CONTRACTOR – MAC PART B, WISCONSIN PHYSICIANS SERVICE CORPORATION (08102)			
Allergy Testing and Allergy Immunotherapy (L36402) (Frequency Guideline exists)	82785 – Gamma globulin (Immunoglobulin) IGE 86003 – Allergen specific IgE; Quantitative or semi-quantitative, each allergen 86008 – Allergen specific IgE: Recombinant ea 86005 – Allergen specific IgE; Qualitative multiallergen screen (dipstick, paddle or disc; CPT non-covered by Medicare) 86001 —Allergen specific IgG; Quantitative or semi-quantitative, each allergen *(CPT non- covered by Medicare)	\$26.00 *Multiple-please refer to fee schedule.	C, F
Biomarkers in Cardiovascular Risk Assessment (L36523)	82172 – Apolipoprotein, Each 82610 – Cystatin C 83090 – Homocysteine 83695 – Lipoprotein (A) 83698 – Lipoprotein-Associated Phospholipase A2 (LP-PLA2) 83700 – Lipoprotein, blood; Electrophoretic separation and quantitation 83701 – Lipoprotein, blood; high resolution fractionations and quantitation of lipoproteins including lipoprotein subclasses when performed 83704 - Lipoprotein, blood; quantitation of lipoprotein particle number(s) (nuclear magnetic resonance spectroscopy) 83721 – Lipoprotein, direct measurement; LDL cholesterol 83880 – Natriuretic peptide 86141 – C-reactive protein; high sensitivity (HSCRP)	\$116.00 \$138.00 \$60.00 \$90.00 \$116.00 \$58.00 \$138.00 \$172.00 \$46.00 \$100.00 \$80.00	C
Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58761)	81514 - Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification (Vaginal Panel by PCR) 87154 – BCID Panels 15-21 Targets 87154 - Torch Panel 87505 – Infectious agent detection by nucleic acid (DNA or RNA) 3-5 targets 87506 - Infectious agent detection by nucleic acid (RNA or DNA) 6-11 targets 87507 – Infectious agent detection by nucleic acid (RNA or DNA) 12-25 targets 87631 – Infectious agent detection by nucleic acid RNA or DNA, 3-5 targets 87631 – Infectious agent Parainfluenza 1-4 by PCR 87633 - Infectious agent detection by nucleic acid (RNA or DNA), 12-25 targets 87636 - Infectious agent detection by nucleic acid RNA or DNA; severe acute respiratory syndrome Coronavirus 2 and Influenza Virus Types A and B, multiplex amplified probe 87637 - Infectious agent detection nucleic acid RNA or DNA; severe acute respiratory syndrome Coronavirus 2, Influenza Types A and B, and Respiratory Syncytial Virus 87801 – Infectious agent detection by nucleic acid (RNA or DNA), multiple organisms; amplified probe(s) technique 87801 – CT, NG by PCR or Bacterial/Fungal by PCR 0202U – BPFAN Respiratory Panel by PCR	\$660.00 \$546.00 \$876.00 \$396.00 \$658.00 \$1,430.00 \$760.00 \$760.00 \$568.00 \$144.00 \$144.00 \$176.00 \$176.00 \$1,244.00	C
Fragile X (A55163)	81243 – FMR1 Fragile X Evaluation to detect abnormal alleles 81244 - FRAGX Fragile X Methylation Analysis	\$250.00 \$130.00	E

Reason for Denial: C = Condition F = Frequency E = Experimental

NCD and LCD with Estimated Patient Cost 1-2025 / Updated 6/20/2025



ALVERNO LABORATORIES

National Coverage Determinations & Indiana Medicare Part B LCD's

Clinical Diagnostic Laboratory Services

Effective: January 2025 (Updated June 20, 2025)

Estimated Patient Cost

Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36815)	81206 – BCR-ABL1 Major Breakpoint Qual or Quant	\$1008.00	C
	81206 - P210 BCR-ABL1	\$572.00	
	81207 – BCR/ABL1 Minor Breakpoint Qual or Quant	\$890.00	
	81219 – CALR (Calreticulin) Gene Analysis, Common Variants in Exon 9	\$250.00	
	81270 – JAK2 (Janus Kinase 2), Gene analysis, (V617F) VARIANT	\$250.00	
	81279 - JAK2 (Janus Kinase 2), Targeted Sequence Analysis (EXONS 12 and 13)	\$250.00	
Genetic Testing for: Factor II Prothrombin Factor V Leiden MTHFR (L36400)	81339 – MPL (MPL Proto-Oncogene, Thrombopoietin Receptor)	\$216.00	E
	81240 - F2 (prothrombin, coagulation factor II) (eg. Hereditary hypercoagulability) gene analysis, 20210G>A variant.	\$316.00	
	81241 - F5 (coagulation factor V)(eg. Hereditary hypercoagulability) gene analysis, Leiden variant.	\$370.00	
	81291 - MTHFR (5,10-methylguanine-DNA methyltransferase)(eg. Hereditary hypercoagulability) gene analysis, common variants (eg. 677T, 1298C)	\$436.00	
Vitamin D Assay Testing (L34658)	82306 – Calcifediol (25-OH Vitamin D-3)	\$110.00	C
	82652 – Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed	\$218.00	

Reason for Denial: C = Condition F = Frequency E = Experimental

NCD and LCD with Estimated Patient Cost 1-2025 / Updated 6/20/2025



ALVERNO LABORATORIES

National Coverage Determinations & Indiana Medicare Part B LCD's

Clinical Diagnostic Laboratory Services

Effective: January 2025 (Updated June 20, 2025)

Estimated Patient Cost

Drug Testing (L34645)	<p>80305: Drug test(s), presumptive, any number of drug classes. Any number of devices or procedures (eg, immunoassay); capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges) includes sample validation when performed, per date of service.</p> <p>80306: Drug test(s), presumptive, any number of drug classes. Any number of devices or procedures (eg, immunoassay); read by instrument assisted direct optical observation (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.</p> <p>80307: Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay {eg, EIA, ELISA, EMIT, FPIA, IA, IMS, RIA}, chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service.</p> <p>80320 – 80377 - Definitive drug classes - Alcohols – drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 7 or more.</p> <p>G0480 - Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative or quantitative, all source(s), includes specimen validity testing, per day. 1-7 drug class(es), including metabolite(s), if performed.</p> <p>G0481 - Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative or quantitative, all source(s), includes specimen validity testing, per day. 8-14 drug classes, including metabolite(s), if performed.</p> <p>G0482: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed</p> <p>G0483: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed</p>	Multiple – please refer to fee schedule.	C
-----------------------	--	--	---

Reason for Denial: C = Condition F = Frequency E = Experimental

NCD and LCD with Estimated Patient Cost 1-2025 / Updated 6/20/2025